References 1. Raskin KA, Schwab JH, Mankin HJ, Springfield DS, Hornicek FJ. Giantcelltumor of bone. J Am Acad Orthop Surg. 2013; 21:118-26. 2. Behjati S, Tarpey PS, Presneau N, Scheipl S, Pillay N, Van Loo P et al. Distinct h3f3a and h3f3b driver mutations define chondroblastoma and giantcelltumor of bone. Nat Genet. 2013; 45:1479-82. 3. Zhen W, Yaotian H, Songjian L, Ge L, Qingliang W. Giantcell tumor of bone. The long-term results of treatment by curettage and bone graft. J Bone Joint Surg (Br). 2004; 86:212-6. 4. Branstetter DG, Nelson SD, Manivel JC et al
zones; appearance of giantcelltumor. The immunohistochemical examination confirmed the
anatomopathological diagnosis adding, therefore, the aggressive character and the local relapse.
The oncologist decided that it did not require oncology treatment but only orthopedic treatment.
Orthopedic treatment required repeated surgery at intervals of about 5 months apart, caused by
tumor recurrence. The first intervention consisted of 1/ 3 distal radius resection and replacement
with a graft harvested from the peroneum. Tumor recurrence after 5 months required
study was to investigate several cases of giantcelltumor of bone
(TCG), chondroblastoma and aneurysmal bone cyst (ABC) by immunohistochemistry (IHC) with a
panel of markers: p63, S-100, CD68, CD56, DOG1, Galectin-1, D2-40, CD34, CD45 and ki-67, some
of which proved to be specifi c for a certain entity.
Material and methods. The cases were retrospectively selected from cases processed in our facility
where the surgical excision material was histopathologically analyzed in optical microscopy using
the usual staining hematoxylin and eosin. The immunohistochemistry